CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

ONCOLOGY

Biocon Biologics has one of the deepest portfolios of biosimilars in the industry. Our long-term investments in R&D have yielded several molecules in oncology, of which three have already been commercialized in markets globally.

Pegfilgrastim

Approved: Registered in 40+ countries across the globe, including the U.S., Europe, Canada, Australia, several MoW markets

Launched: Commercialized in the U.S., Europe, Canada, Australia

Preclinical

Clinical

Filed

Approved

Launched

Trastuzumab

Approved: Registered in 70+ countries across the globe, including the U.S., Europe, Canada, Australia, and several markets in most of the world (MoW).

Launched: Commercialized in the U.S., Europe, Australia, Canada, India, Brazil, Argentina, Turkey, Indonesia etc.

Preclinical

Clinical

Filed

Approved

Launched

Bevacizumab

Approved: Registered in 40 countries across the globe, including Europe, Canada, the UK, Australia, countries across most of the world (MoW) markets

Launched: Commercialized in Europe, Canada, India, Malaysia

Preclinical

Clinical

Filed

Approved

Launched

Denosumab

Preclinical

Clinical

Filed

Approved

Launched

Pertuzumab

Preclinical

Clinical

Filed

Approved

Launched

Share